Terushige Iike
Corporate Officer/Principal bei EISAI CO., LTD.
Aktive Positionen von Terushige Iike
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| EISAI CO., LTD. | Corporate Officer/Principal | 01.04.1986 | - |
Karriereverlauf von Terushige Iike
Ehemalige bekannte Positionen von Terushige Iike
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
H3 Biomedicine, Inc.
 H3 Biomedicine, Inc. Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., H3 Biomedicine, Inc. is a precision oncology research and development subsidiary based in Cambridge, MA. The company is uniquely positioned to integrate real-world clinical evidence with the latest advances in cancer genomics. H3 is developing a pipeline of highly targeted, breakthrough medicines that have the potential to impact the future of cancer care and treatment. The CEO of the company is Takashi Owa. | Direktor/Vorstandsmitglied | 01.05.2018 | - |
| Vorstandsvorsitzender | 01.05.2018 | - |
Statistik
International
| Japan | 2 |
| Vereinigte Staaten | 2 |
Operativ
| Corporate Officer/Principal | 1 |
| Director/Board Member | 1 |
| Chief Executive Officer | 1 |
Sektoral
| Health Technology | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| EISAI CO., LTD. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
H3 Biomedicine, Inc.
H3 Biomedicine, Inc. Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., H3 Biomedicine, Inc. is a precision oncology research and development subsidiary based in Cambridge, MA. The company is uniquely positioned to integrate real-world clinical evidence with the latest advances in cancer genomics. H3 is developing a pipeline of highly targeted, breakthrough medicines that have the potential to impact the future of cancer care and treatment. The CEO of the company is Takashi Owa. | Health Technology |
- Börse
- Insiders
- Terushige Iike
- Erfahrung
